SOPHiA GENETICS (NASDAQ:SOPH) Research Coverage Started at Guggenheim

by · The Cerbat Gem

Guggenheim started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH – Free Report) in a report released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.

Several other analysts have also issued reports on the stock. Royal Bank of Canada reaffirmed an outperform rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Wednesday, March 6th. BTIG Research upped their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a buy rating in a report on Wednesday, March 6th.

Check Out Our Latest Report on SOPH

SOPHiA GENETICS Stock Down 1.3 %

Shares of SOPH stock opened at $4.58 on Thursday. The company’s fifty day simple moving average is $4.85 and its 200-day simple moving average is $4.83. The firm has a market cap of $299.44 million, a PE ratio of -4.09 and a beta of 1.09. SOPHiA GENETICS has a 12 month low of $2.13 and a 12 month high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. SOPHiA GENETICS had a negative net margin of 113.71% and a negative return on equity of 47.56%. The business had revenue of $15.78 million for the quarter, compared to analyst estimates of $16.80 million. On average, equities analysts predict that SOPHiA GENETICS will post -1.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 2.6% during the fourth quarter. Principal Financial Group Inc. now owns 995,500 shares of the company’s stock worth $4,689,000 after buying an additional 24,837 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in SOPHiA GENETICS by 90.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock worth $65,000 after buying an additional 6,552 shares in the last quarter. Legato Capital Management LLC acquired a new stake in SOPHiA GENETICS during the fourth quarter worth about $235,000. Essex Investment Management Co. LLC acquired a new stake in SOPHiA GENETICS during the fourth quarter worth about $584,000. Finally, Federated Hermes Inc. grew its stake in SOPHiA GENETICS by 100.0% during the third quarter. Federated Hermes Inc. now owns 160,000 shares of the company’s stock worth $408,000 after buying an additional 80,000 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

Further Reading